Clinical Trial Search

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale

Primary: Marijuana Abstinence — 0; 2 Participants

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed

Primary: Time Line Follow Back (TLFB) for Cannabis Use — 1.921; 1.768; 1.201; 1.066 times/day of self-reported cannabis use

Primary: Change in Kessler Psychological Distress Scale (K10) Score — 6.4; 4.5 score on a scale

Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient

Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale

Primary: Mean Difference in the Total Number of Errors From Paired Associates Learning (PAL) Module Averaged Over Weeks 1, 2, 3, and 4 — 5.6; 6.2; 5.9 score on a scale — p=0.215

Primary: Marijuana Craving Questionnaire-Short Form Score as a Measure of Behavioral Craving — 45.8; 45.2; 27.7; 22.6 score on a scale

Primary: Time to Cannabis Use Relapse — 1; 1 days

Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds

Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33

Primary: Tolerability — 0; 0; 0 Participants

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029

Primary: Brain Reward Circuit Activation on fMRI Scan — 0.05; 0.14; 0.18; 0.12 z-score — p=0.87

Primary: Change in Yale-Brown Obsessive Compulsive Scale — 24.0; 14.2; 2.5; 11.2 score on a scale

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Percentage of Urine Tests With Negative Cannabinoid Results During Treatment — 9.4; 14.0 Percentage

Primary: Number (%) of Participants Who Started and Completed Treatment — 8; 8 Participants